tbuckley/cabot-search huggingface dataset:
Comparison of General Surgical Practice Size and Setting in 2017 vs 2013 in the US
Authors: Thomas C. Tsai, Benjamin H. Jacobson, Evan M. Benjamin, Jose F. Figueroa
Journal: JAMA Network Open (2021)

<h3>Importance</h3> As health care delivery markets have changed and new payment models have emerged, physicians in many specialties have consolidated their practices, but whether this consolidation has occurred in surgical practices is unknown. <h3>Objective</h3> To examine changes in the size of surgical practices, market-level factors associated with this consolidation, and how place of service for surgical care delivery varies by practice size. <h3>Design, Setting, and Participants</h3> A cross-sectional study of Medicare Data on Provider Practice and Specialty from January 1 to December 31, 2013, compared with January 1 to December 31, 2017, was conducted on all general surgeon practices caring for patients enrolled in Medicare in the US. Data analysis was performed from November 4, 2019, to January 9, 2020. <h3>Exposures</h3> Practice sizes in 2013 and 2017 were compared relative to hospital market concentration measured by the Herfindahl-Hirschman Index in the hospital referral region. <h3>Main Outcomes and Measures</h3> The primary outcome was the change in size of surgical practices over the study period. Secondary outcomes included change in surgical practice market concentration and the place of service for provision of surgical care stratified by surgical practice size. <h3>Results</h3> From 2013 to 2017, the number of surgical practices in the US decreased from 10 432 to 8451. The proportion of surgeons decreased in practices with 1 (from 26.2% to 17.4%), 2 (from 8.3% to 6.6%), and 3 to 5 (from 18.0% to 16.5%) surgeons, and the proportion of surgeons in practices with 6 or more surgeons increased (from 47.6% to 59.5%). Hospital concentration was associated with an increase in the size of the surgical practice. Each 10% increase in the hospital market concentration was associated with an increase of 0.204 surgeons (95% CI, 0.020-0.388 surgeons;<i>P</i> = .03) per practice from 2013 to 2017. Similarly, a 10% increase in the hospital-level HHI was associated with an increase in the surgical practice HHI of 0.023 (95% CI, 0.013-0.033;<i>P</i> &lt; .001). Large surgical practices increased their share of Medicare services provided from 36.5% in 2013 to 45.6% in 2017. Large practices (31.3% inpatient in 2013 to 33.1% in 2017) were much more likely than small practices (19.0% inpatient in 2013 to 17.7% in 2017) to be based in hospital settings and this gap widened over time. <h3>Conclusions and Relevance</h3> Surgeons have increasingly joined larger practices over time, and there has been a significant decrease in solo, small, and midsize surgical practices. The consolidation of surgeons into larger practices appears to be associated with hospital market concentration in the same market. Although overall care appears to be more hospital based for larger practices, the association between the consolidation of surgical practices and patient access and outcomes should be studied.
Atlas of the External Diseases of the Eye. Including a Brief Treatise on the Pathology and Treatment.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION IN YOUNG PATIENTS: INSIGHTS FROM THE PROGRESS-CTO REGISTRY
Authors: Ilias Nikolakopoulos, Evangelia Vemmou, Judit Karacsonyi, Khaldoon Alaswad, Dimitrios Karmpaliotis, Daniel Schimmel, Keith Benzuly, James Flaherty, Oleg Krestianinov, Dmitrii Khelimskii, Nidal Abi Rafeh, ElGuindy Ahmed, Omer Goktekin, Sevket Gorgulu, Niranjan Reddy, Jaikirshan Khatri, Farouc Jaffer, Michael Koutouzis, Ioannis Tsiafoutis, Robert Riley, James Choi, Wissam Jaber, Habib Samady, M. Nicholas Burke, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2021)
Abstract 10251: Aortic Stenosis Incidence, Management and Outcomes
Authors: Emily P Hiltner, Stavros Zinonos, Davit Sargsyan, John B Kostis, Javier Cabrera, Nora Cosgrove, Abel E Moreyra, Issam Moussa, William J Kostis
Journal: Circulation (2019)

Background: Operative management of aortic stenosis (AS) evolved over the last 20 years, and it is unknown how those advances changed outcomes and management of patients with AS. We aimed to define...
Long-Term Prognosis of Patients With Resected Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung
Authors: Masaya Yotsukura, Hisao Asamura, Noriko Motoi, Jumpei Kashima, Yukihiro Yoshida, Kazuo Nakagawa, Kouya Shiraishi, Takashi Kohno, Yasushi Yatabe, Shun-ichi Watanabe
Journal: Journal of Thoracic Oncology (2021)
Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial
Authors: Ji Won Park, Sung-Bum Kang, Jie Hao, Seok-Byung Lim, Hyo Seong Choi, Duck-Woo Kim, Hee Jin Chang, Dae Yong Kim, Kyung Hae Jung, Tae-You Kim, Gyeong Hoon Kang, Eui Kyu Chie, Sun Young Kim, Dae Kyung Sohn, Jae-Sung Kim, Hye Seung Lee, Jee Hyun Kim, Seung-Yong Jeong, Jae Hwan Oh
Journal: The Lancet. Gastroenterology & hepatology (2021)
CONGENITAL HEART DISEASE IN ADULTS - A NEW PROFILE INSPIRES A NEW PARADIGM
Authors: Layara Fernanda Lipari Dinardi, Marcela Devido, Thiago Vicente Pereira, Gabriel Leiros Romano, Leina Zorzanelli, Ana Maria Thomaz, Ana Cristina Tanaka, Adailson Vagner da Silva Siqueira, Nana Miura Ikari, Estela Azeka
Journal: Journal of the American College of Cardiology (2021)
GLOBAL LONGITUDINAL STRAIN IMPROVES RISK ASSESSMENT AFTER ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: A COMPARATIVE PROGNOSTIC EVALUATION OF LEFT VENTRICULAR FUNCTIONAL PARAMETERS
Authors: Magdalena Holzknecht, Martin Reindl, Christina Tiller, Sebastian Johannes Reinstadler, Ivan Lechner, Mathias Pamminger, Johannes P Schwaiger, Gert Klug, Axel Bauer, Agnes Mayr, Bernhard Metzler
Journal: Journal of the American College of Cardiology (2021)
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
Authors: Scott T. Tagawa, Arjun V. Balar, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Yohann Loriot, Aude Fléchon, Rohit K. Jain, Neeraj Agarwal, Manojkumar Bupathi, Philippe Barthelemy, Philippe Beuzeboc, Phillip Palmbos, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Quan Hong, Trishna Goswami, Loretta M. Itri, Petros Grivas
Journal: Journal of Clinical Oncology (2021)

Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% with a median overall survival (OS) of 7-8 months. Sacituzumab govitecan (SG) is a TROP-2-directed antibody-drug conjugate with an SN-38 payload that has shown preliminary activity in mUC.
PRESENCE OF IMPLANTABLE CARDIAC DEVICES: IMPLICATIONS FOR ELDERLY PATIENTS PRESENTING WITH TRAUMATIC INJURIES
Authors: Demian Jideofor Omeh, Rezwan Munshi, Tanzim Bhuiya, Brian Berookhim, Ashley Roper, Viliane Vilcant, Swapna Munnangi, Elisa Szydziak, Ofek Hai, Roman Zeltser, Jody C. DiGiacomo, Amgad Makaryus
Journal: Journal of the American College of Cardiology (2021)
PREOP MANAGEMENT OF A PATIENT UNDERGOING OPEN AAA REPAIR FOUND TO HAVE CTO OF PROXIMAL LAD WITH HIGH GRADE PDA AND PLV COLLATERALS - SHOULD WE INTERVENE
Authors: Adnan Yousaf, Sunil Vasireddi, Ahmad Jabri, Zahra Khaled, Muhammad Ali, Meera Kondapaneni, Aisha Siraj
Journal: Journal of the American College of Cardiology (2021)
Impact of Anesthesia Strategy and Valve Type on Clinical Outcomes After Transcatheter Aortic Valve Replacement
Authors: Hans-Josef Feistritzer, Thomas Kurz, Georg Stachel, Philipp Hartung, Philipp Lurz, Ingo Eitel, Christoph Marquetand, Holger Nef, Oliver Doerr, Ursula Vigelius-Rauch, Alexander Lauten, Ulf Landmesser, Sascha Treskatsch, Mohamed Abdel-Wahab, Marcus Sandri, David Holzhey, Michael Borger, Jörg Ender, Hüseyin Ince, Alper Öner, Roza Meyer-Saraei, Rainer Hambrecht, Harm Wienbergen, Andreas Fach, Thomas Augenstein, Norbert Frey, Inke R. König, Reinhard Vonthein, Anne-Kathrin Funkat, Astrid E. Berggreen, Matthias Heringlake, Steffen Desch, Suzanne de Waha-Thiele, Holger Thiele
Journal: Journal of the American College of Cardiology (2021)
TRANSITION TO ORAL DIURETICS PRIOR TO DISCHARGE IS NOT ASSOCIATED WITH IMPROVED 30-DAY OUTCOMES IN PATIENTS HOSPITALIZED WITH DECOMPENSATED SYSTOLIC HEART FAILURE
Authors: Adeba Mohammad, Shuktika Nandkeolyar, Dennis Grewal, Antoine Sakr, Ahmed Seliem, Liset Stoletniy, Dmitry Abramov
Journal: Journal of the American College of Cardiology (2021)
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
Authors: Otto Metzger Filho, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia Dell'Orto, Leila Russo, Tari A. King, Kornelia Polyak, Franziska Michor, Eric P. Winer, Ian E. Krop
Journal: Cancer Discovery (2021)

Abstract Intratumor heterogeneity is postulated to cause therapeutic resistance. To prospectively assess the impact of HER2 (ERBB2) heterogeneity on response to HER2-targeted therapy, we treated 164 patients with centrally confirmed HER2-positive early-stage breast cancer with neoadjuvant trastuzumab emtansine plus pertuzumab. HER2 heterogeneity was assessed on pretreatment biopsies from two locations of each tumor. HER2 heterogeneity, defined as an area with ERBB2 amplification in &amp;gt;5% but &amp;lt;50% of tumor cells, or a HER2-negative area by FISH, was detected in 10% (16/157) of evaluable cases. The pathologic complete response rate was 55% in the nonheterogeneous subgroup and 0% in the heterogeneous group (P &amp;lt; 0.0001, adjusted for hormone receptor status). Single-cell ERBB2 FISH analysis of cellular heterogeneity identified the fraction of ERBB2 nonamplified cells as a driver of therapeutic resistance. These data suggest HER2 heterogeneity is associated with resistance to HER2-targeted therapy and should be considered in efforts to optimize treatment strategies. Significance: HER2-targeted therapies improve cure rates in HER2-positive breast cancer, suggesting chemotherapy can be avoided in a subset of patients. We show that HER2 heterogeneity, particularly the fraction of ERBB2 nonamplified cancer cells, is a strong predictor of resistance to HER2 therapies and could potentially be used to optimize treatment selection. See related commentary by Okines and Turner, p. 2369. This article is highlighted in the In This Issue feature, p. 2355
The association of sexual orientation with prostate, breast, and cervical cancer screening and diagnosis.
Authors: Michael Joseph Herriges, Ruben Pinkhasov, Keren Lehavot, Oleg Shapiro, Joseph M Jacob, Thomas Sanford, Nick Liu, Gennady Bratslavsky, Hanan Goldberg
Journal: Journal of Clinical Oncology (2021)

129 Background: Data on heterogeneity in cancer screening and diagnosis rates among lesbians/gays and bisexuals is lacking. Recent studies showed that lesbians/gays and bisexuals have decreased healthcare utilization compared to heterosexual counterparts and continue to experience discrimination in healthcare. Few studies have examined how sexual orientation impacts cancer screening and prevalence. We, therefore, investigated the association between sexual orientation and prevalent sex-specific cancer including prostate, breast, and cervical cancer. Methods: This was a cross-sectional survey-based US study, including men and women aged 18+ from the Health Information National Trends Survey (HINTS) database between 2017-2019. The primary endpoint was individual-reported prostate, breast, and cervical cancer screening and prevalence rates among heterosexual and LGB men and women. Multivariable logistic regression analyses assessed association of various covariates with undergoing screening and diagnosis of these cancers. Results: Overall, 4,441 and 6,333 heterosexual men and women, respectively, were compared to 225 and 213 lesbian/gay and bisexual men and women, respectively. Lesbians/gays and bisexuals were younger and less likely to be screened for prostate, breast, and cervical cancer than heterosexuals. A higher proportion of heterosexual women than lesbian and bisexual women were screened for cervical cancer with pap smears (95.36% vs. 90.48% and 86.11%, p = &lt; 0.001) and breast cancer with mammograms (80.74% vs. 63.81% and 45.37%, p = &lt; 0.001). Similarly, a higher proportion of heterosexual men than gay and bisexual men were screened for prostate cancer with PSA blood tests (41.27% vs. 30.53% and 27.58%, p = &lt; 0.001). Conclusions: Lesbians/gays and bisexuals in the US may be less likely to undergo screening of sex-specific prevalent malignancies, including prostate, breast, and cervical cancer. Healthcare professionals should be encouraged to improve cancer screening among lesbians/gays and bisexuals.
MEGASTRUCTURES IN ISCHEMIC HEART DISEASE. MASSIVE LEFT VENTRICULAR PSEUDOANEURYSM WITH SEVERE MITRAL REGURGITATION
Authors: Andrea Teira Calderon, Adrián Margarida, Ignacio Santiago, Indira Cabrera, Sofia Gonzalez Lizarbe, Teresa Catalina Borderias Villarroel, Jon Zubiaur, Raquel Perez, Aritz Gil Ongay, Gonzalo Martín, Valentin Tascon Quevedo, Gerardo Blanco, Luis Javier Ruiz
Journal: Journal of the American College of Cardiology (2021)
Azacitidine Directly Acts on the Mesenchymal Stromal Cell Compartment in Myelodysplastic Syndromes to Alter Niche Function and Suppress Malignant Hematopoeitic Stem/Progenitor Cells
Authors: Catharina Wenk, Anne-Kathrin Garz, Christina Huberle, Sonja Grath, Denis Witham, Marie Weickert, Julia Niggemeyer, Judith Hecker, Michele Kyncl, Catharina Müller-Thomas, Christopher Mulholland, Robert A.J. Oostendorp, Klaus H. Metzeler, Christian Peschel, Katharina S Götze
Journal: Blood (2017)
STROKE DURING PRIMARY PERCUTANEOUS CORONARY INTERVENTION: INCIDENCE AND LONG-TERM OUTCOMES FROM THE MIDWEST STEMI CONSORTIUM
Authors: Michael Megaly, Brynn Okeson, Ross Garberich, Larissa Stanberry, Scott Sharkey, Frank Aguirre, Mark Tannenbaum, Raviteja Guddeti, Edward Tannenbaum, Timothy Smith, Timothy Henry, Santiago Garcia
Journal: Journal of the American College of Cardiology (2021)
COMPARISON OF RISK PROFILES OF WOMEN WITH INOCA DIAGNOSED BY CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY VS INVASIVE CORONARY ANGIOGRAPHY - A SUBSTUDY OF THE WOMEN’S ISCHEMIA TRIAL TO REDUCE EVENTS IN NON-OBSTRUCTIVE CORONARY ARTERY DISEASE (WARRIOR)
Authors: Suvasini Lakshmanan, Janet Wei, Galen Cook-Wiens, Andre Rogatko, Eileen Handberg, Carl Pepine, Leslee Shaw, Matthew Budoff, C. Noel Bairey Merz
Journal: Journal of the American College of Cardiology (2021)
IMPACT OF LEFT BUNDLE BRANCH AREA PACING VERSUS BIVENTRICULAR PACING: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Jian Liang Tan, Justin Lee, Vittorio Terrigno, Benjamin Saracco, Shivam Saxena, Jonathan Krathen, Yong-Mei Cha, Andrea Russo
Journal: Journal of the American College of Cardiology (2021)
CARDIOMETABOLIC PROFILES OF TRANSGENDER INDIVIDUALS TAKING GENDER-AFFIRMING HORMONE THERAPY IN THE TRANSGENDER HEALTH AGING STUDY AND REGISTRY
Authors: Nyein Chan Swe, Samihah Ahmed, Karina Ziskovich, Natalie E Cusano, Minghao Liu, Leonid Poretsky, Eugenia Gianos
Journal: Journal of the American College of Cardiology (2021)
ROUTINE USE OF ASPIRATION THROMBECTOMY DEVICE “PENUMBRA” IN MYOCARDIAL INFARCTION (ROPUST) STUDY
Authors: Ahmad Tarek Chami, Tony Dong, Nour Tashtish, Haytham Mously, Mehdi Shishehbor, Anjan Gupta
Journal: Journal of the American College of Cardiology (2021)
Abstract 16105: Depression Modulates Polygenic Risk of Cardiovascular and Cardiometabolic Disease
Authors: Michael C Honigberg, Amy Sarma, Nandita Scott, Malissa J Wood, Pradeep Natarajan
Journal: Circulation (2020)

Introduction: Depression is associated with an increased risk of coronary artery disease (CAD). Whether depression modifies genetic risk of cardiovascular and cardiometabolic disease is unknown. Methods: We included genotyped, unrelated European ancestry individuals in the UK Biobank. Using genome-wide significant single nucleotide polymorphisms (SNPs) from studies external to the UK Biobank, we generated polygenic risk scores (PRS) for coronary artery disease (CAD, 74 SNPs), hypertension (75 SNPs), type 2 diabetes (T2D, 64 SNPs), atrial fibrillation (25 SNPs), and ischemic stroke (11 SNPs). Participants were stratified by PRS for each condition as low (quintile 1), intermediate (quintiles 2-4), and high (quintile 5) genetic risk. Cox models tested the association of depression frequency with each incident condition among individuals with high PRS, with adjustment for age, sex, the first 20 principal components, genotyping array, and Townsend deprivation index. Additional models further adjusted for health behaviors (exercise, tobacco and alcohol use, vegetable and fresh fruit intake) and tested associations across the PRS spectrum. Results: Among 348,083 individuals, 78,664 (22.6%) reported depression in the past 2 weeks, including 14,776 (4.2%) with depression more than half of days. Depression burden modified the risk of incident CAD across the spectrum of CAD polygenic risk (Figure 1A). Among individuals with high PRS, lack of depression was associated with lower risk of incident CAD (HR 0.70, 95% 0.58-0.86), hypertension (HR 0.58, 95% CI 0.50-0.67), T2D (HR 0.48, 95% CI 0.41-0.55), and atrial fibrillation (HR 0.74, 95% CI 0.62-0.89) compared to those with a high burden of depression. These risk reductions were minimally attenuated after further adjustment for health behaviors (Figure 1B). Conclusions: Lower burden of depression was associated was decreased risks of cardiovascular disease among individuals at high genetic cardiovascular risk.
SEX BASED DIFFERENCES IN OUTCOMES OF PATIENTS WITH CHRONIC LIMB ISCHEMIA UNDERGOING ENDOVASCULAR TREATMENT
Authors: Harsh Patel, Aakash Sheth, Monil Majmundar, Kirtenkumar Patel, Krunalkumar Patel, Samarthkumar Thakkar, Devina Adalja, Raj Patel, Toralben Patel, Fahira Parisha, Mamik Patel, Virmitra Desai, Rajkumar Doshi, Sidakpal Panaich
Journal: Journal of the American College of Cardiology (2021)
<i>Mycobacterium tuberculosis</i> borderline <i>rpoB</i> mutations: emerging from the unknown
Authors: Armand Van Deun, Tom Decroo, Kya Jai Maug Aung, Mohamed Anwar Hossain, Mourad Gumusboga, Willem Bram De Rijk, Sabira Tahseen, Bouke Catherine de Jong, Leen Rigouts
Journal: European Respiratory Journal (2021)

<b>Despite their name, borderline <i>rpoB</i> mutations are correlated with unfavourable outcomes when rifampicin-throughout treatment is used. They may become the drivers of rifampicin-resistant tuberculosis. Second-line treatment is recommended.</b> https://bit.ly/3nbkZjt
Abstract 15004: A Mindfulness Intervention for Paroxysmal Atrial Fibrillation Diminishes Illness Perception, Improves AF Knowledge and Reduces CV Risk
Authors: Linda K Ottoboni, Mintu Turakhia, Frederick M Hecht, Janine Cataldo, Jill Howie-Esquivel
Journal: Circulation (2018)

Introduction: Paroxysmal atrial fibrillation (PAF) can cause a significant shift in health perception, from wellness to illness. A strong illness perception can be disabling and contribute to AF ri...
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Authors: Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang, Gerard M. J. Bos, Wilfred T. V. Germeraad
Journal: Journal of Hematology & Oncology (2021)

Abstract Due to their efficient recognition and lysis of malignant cells, natural killer (NK) cells are considered as specialized immune cells that can be genetically modified to obtain capable effector cells for adoptive cellular treatment of cancer patients. However, biological and technical hurdles related to gene delivery into NK cells have dramatically restrained progress. Recent technological advancements, including improved cell expansion techniques, chimeric antigen receptors (CAR), CRISPR/Cas9 gene editing and enhanced viral transduction and electroporation, have endowed comprehensive generation and characterization of genetically modified NK cells. These promising developments assist scientists and physicians to design better applications of NK cells in clinical therapy. Notably, redirecting NK cells using CARs holds important promise for cancer immunotherapy. Various preclinical and a limited number of clinical studies using CAR-NK cells show promising results: efficient elimination of target cells without side effects, such as cytokine release syndrome and neurotoxicity which are seen in CAR-T therapies. In this review, we focus on the details of CAR-NK technology, including the design of efficient and safe CAR constructs and associated NK cell engineering techniques: the vehicles to deliver the CAR-containing transgene, detection methods for CARs, as well as NK cell sources and NK cell expansion. We summarize the current CAR-NK cell literature and include valuable lessons learned from the CAR-T cell field. This review also provides an outlook on how these approaches may transform current clinical products and protocols for cancer treatment.